Capital International Investors Purchases 5,698 Shares of Thermo Fisher Scientific Inc. $TMO

Capital International Investors boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.6% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 915,007 shares of the medical research company’s stock after acquiring an additional 5,698 shares during the period. Capital International Investors owned 0.24% of Thermo Fisher Scientific worth $443,789,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TMO. Legal & General Group Plc grew its stake in Thermo Fisher Scientific by 5.3% in the 3rd quarter. Legal & General Group Plc now owns 2,462,988 shares of the medical research company’s stock valued at $1,194,598,000 after buying an additional 124,432 shares in the last quarter. Banque Cantonale Vaudoise boosted its holdings in shares of Thermo Fisher Scientific by 0.5% in the third quarter. Banque Cantonale Vaudoise now owns 7,127 shares of the medical research company’s stock worth $3,457,000 after acquiring an additional 36 shares during the period. Fieldview Capital Management LLC purchased a new position in shares of Thermo Fisher Scientific in the third quarter valued at $5,091,000. WINTON GROUP Ltd raised its stake in shares of Thermo Fisher Scientific by 82.7% during the 3rd quarter. WINTON GROUP Ltd now owns 29,800 shares of the medical research company’s stock valued at $14,454,000 after purchasing an additional 13,486 shares during the period. Finally, Navalign LLC lifted its holdings in Thermo Fisher Scientific by 2.5% during the 3rd quarter. Navalign LLC now owns 2,217 shares of the medical research company’s stock worth $1,075,000 after purchasing an additional 54 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 1.9%

Shares of TMO opened at $500.14 on Wednesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.89 and a quick ratio of 1.53. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $643.99. The company has a market capitalization of $185.79 billion, a P/E ratio of 28.19, a P/E/G ratio of 2.94 and a beta of 0.96. The firm’s 50 day simple moving average is $564.13 and its 200 day simple moving average is $549.24.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, January 29th. The medical research company reported $6.57 EPS for the quarter, topping analysts’ consensus estimates of $6.45 by $0.12. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The firm had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.95 billion. During the same quarter in the prior year, the firm earned $6.10 EPS. The business’s revenue for the quarter was up 7.2% compared to the same quarter last year. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th will be paid a $0.47 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Friday, March 13th. Thermo Fisher Scientific’s payout ratio is presently 9.70%.

Insider Activity

In other news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $541.20, for a total transaction of $216,480.00. Following the transaction, the executive vice president directly owned 20,752 shares of the company’s stock, valued at approximately $11,230,982.40. This trade represents a 1.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 5,000 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

TMO has been the topic of several analyst reports. HSBC upgraded Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Monday, December 1st. TD Cowen reduced their price objective on shares of Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating for the company in a research note on Friday, January 30th. UBS Group reiterated a “neutral” rating and issued a $615.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. KeyCorp raised shares of Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price target for the company in a report on Sunday, December 7th. Finally, Morgan Stanley upped their price target on shares of Thermo Fisher Scientific from $656.00 to $670.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $633.68.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.